A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy
Latest Information Update: 21 Mar 2025
At a glance
- Drugs Remibrutinib (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 18 Mar 2025 Status changed from active, no longer recruiting to completed.
- 10 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 31 Dec 2024 Planned End Date changed from 2 May 2025 to 8 Mar 2025.